We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


12 Jan 2022 By Robyn Mak

The sector has been immune to U.S.-China tensions that sickened cross-border tech investments; in fact giants like $27 bln cancer treatment specialist BeiGene are thriving thanks to global tie-ups. Decoupling looks unlikely, but political risks are rising fast.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)